91 related articles for article (PubMed ID: 15934518)
21. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
Roukos DH; Tzakos A; Zografos G
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
[No Abstract] [Full Text] [Related]
22. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
Kerbel RS
Science; 2006 May; 312(5777):1171-5. PubMed ID: 16728631
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of hypertension associated with BAY 43-9006.
Veronese ML; Mosenkis A; Flaherty KT; Gallagher M; Stevenson JP; Townsend RR; O'Dwyer PJ
J Clin Oncol; 2006 Mar; 24(9):1363-9. PubMed ID: 16446323
[TBL] [Abstract][Full Text] [Related]
24. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
25. [Angiogenic inhibitors and radiotherapy: from the concept to the clinical trial].
Cohen-Jonathan Moyal E
Cancer Radiother; 2009 Oct; 13(6-7):562-7. PubMed ID: 19695923
[TBL] [Abstract][Full Text] [Related]
26. [Angiogenesis inhibitors and radiation therapy: concept and preliminary results].
Mazeron R; Bourhis J; Deutsch E
Bull Cancer; 2009 Mar; 96(3):299-310. PubMed ID: 19318308
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.
Tong FK; Chow S; Hedley D
Cytometry B Clin Cytom; 2006 May; 70(3):107-14. PubMed ID: 16498671
[TBL] [Abstract][Full Text] [Related]
28. Tumoral angiogenesis: review of the literature.
Khosravi Shahi P; Fernández Pineda I
Cancer Invest; 2008 Feb; 26(1):104-8. PubMed ID: 18181052
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib: new indication. For some patients with liver cancer.
Prescrire Int; 2009 Apr; 18(100):59. PubMed ID: 19585718
[TBL] [Abstract][Full Text] [Related]
30. Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody.
Kuwada SK
Curr Opin Mol Ther; 2007 Feb; 9(1):92-8. PubMed ID: 17330407
[TBL] [Abstract][Full Text] [Related]
31. Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.
Colevas AD; Scharf O; Schoenfeldt M
Oncology (Williston Park); 2004 Dec; 18(14):1778, 1781-2, 1784. PubMed ID: 15700626
[No Abstract] [Full Text] [Related]
32. Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.
Kelland L
Curr Opin Mol Ther; 2007 Feb; 9(1):86-91. PubMed ID: 17330406
[TBL] [Abstract][Full Text] [Related]
33. Severe cutaneous reaction to sorafenib: induction of tolerance.
Bauer C; Przybilla B; Ruëff F
Acta Derm Venereol; 2008; 88(6):627-8. PubMed ID: 19002355
[No Abstract] [Full Text] [Related]
34. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.
Folkman J
Exp Cell Res; 2006 Mar; 312(5):594-607. PubMed ID: 16376330
[TBL] [Abstract][Full Text] [Related]
35. Clinical trials. Referral resource. Clinical trials assessing quality of life.
Cheson BD; McCabe MS; Phillips PH
Oncology (Williston Park); 1995 Nov; 9(11):1171-4, 1176, 1178. PubMed ID: 8703685
[No Abstract] [Full Text] [Related]
36. Sorafenib-induced erythema multiforme.
MacGregor JL; Silvers DN; Grossman ME; Sherman WH
J Am Acad Dermatol; 2007 Mar; 56(3):527-8. PubMed ID: 17241689
[No Abstract] [Full Text] [Related]
37. Clinical trials referral resource. Clinical trials of dolastatin-10.
Wright JJ; Blatner G; Cheson BD
Oncology (Williston Park); 1999 Jan; 13(1):68-70, 75. PubMed ID: 10027199
[No Abstract] [Full Text] [Related]
38. Clinical trials referral resource. Current clinical trials in CNS tumors.
Kaplan RS; Schoenfeldt M
Oncology (Williston Park); 2004 Mar; 18(3):322, 327, 330 passim. PubMed ID: 15065702
[No Abstract] [Full Text] [Related]
39. Clinical trials referral resource. Pediatric studies.
Cheson BD
Oncology (Williston Park); 1991 Jan; 5(1):41-4, 47-53. PubMed ID: 1828687
[No Abstract] [Full Text] [Related]
40. Clinical trials referral resource. Clinical trials being offered at City of Hope National Medical Center. Part 3.
Oncology (Williston Park); 1994 Jul; 8(7):52, 55. PubMed ID: 7917839
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
